Cellular starvation kills treatment-resistant breast cancer

November 21, 2016 by Kara Manke
In this microscope view of cancerous tissue, purple-colored breast cancer cells are nestled within ribbons of pink connective tissue. Credit: Dr. Cecil Fox, National Cancer Institute, NIH

Cancer rewires the metabolism of tumor cells, converting them into lean, mean, replicating machines. But like Olympic athletes who rely on special diets to perform, tumor cells' amped-up metabolism can also make them dependent on specific nutrients for survival.

For years, scientists have been trying to identify and understand these cellular cravings in hopes of creating new cancer treatments that work by blocking off access to necessary nutrients and starving tumors to death.

In a new study, Duke University scientists report that from a vicious and treatment-resistant form of breast cancer, called triple negative breast cancer (TNBC), die off rapidly when deprived of a key nutrient called cystine. By examining the cause of cell death, they found that this "cystine addiction" is triggered by a mechanism that many kinds of tumor cells use to break away and migrate to new locations in the body.

"This process is well-known and shows up in metastatic cancer cells, and what we found is that it also makes the cells cystine-addicted," said Jen-Tsan Ashley Chi, associate professor of molecular genetics and microbiology at the Duke University School of Medicine and senior author on the study. "This is great news, because these are the cells that we really want to get rid of."

The results indicate that blocking cystine uptake may be an effective way of treating not only triple negative breast cancer, but other aggressive cancers that use this pathway during metastasis. The study appeared online Nov. 21 in Oncogene.

Patients diagnosed with triple negative breast cancer, which constitute about 10 to 20 percent of all breast cancer cases, have few treatment options outside of surgery and chemotherapy. That is because the most successful breast cancer therapies target two of three receptors commonly found in —estrogen receptor, progesterone receptor, or the Her2/neu receptor—but triple negative breast cancer cells lack all three.

Some studies have hinted that these cells cannot survive without cystine, a molecule built from two copies of the amino acid cysteine linked together.

Earlier this year, Chi's group published a study showing that cells from an aggressive form of kidney cancer are addicted to cystine. To find out if this was also true for triple negative breast cancer, Xiaohu Tang, a previous postdoctoral fellow in Chi lab, submitted both triple-negative and estrogen-positive breast cancer cells to a nutrient deprivation test: growing batches of each cell type in a series of different growth media, each missing just one out of 15 key amino acids.

Most of the cells showed little reaction to these small changes in diet, Chi said. But there was one notable exception.

"The triple negative breast cancer cells were very sensitive to cystine," Chi said. "So if you removed cystine, they just rapidly died, while the other cells didn't care."

They subjected the cells to a battery of genetic analyses to pinpoint the cause. They found that the cystine addiction is linked to a process called the epithelial to mesenchymal transition (EMT), a bit of genetic programming that allows stationary epithelial cells, usually stuck in place by tough, zipper-like molecules, to transform themselves into roving .

The triple negative , along with a number of other types of cancer cells, tap into this process to break away from their neighbors and metastasize to spread throughout the body, Chi says. But it appears that this process also triggers a cellular signaling pathway that leads to rapid death as soon as cystine is not available.

"We found that this transition between epithelial and mesenchymal basically opens up a signaling difference that makes the cells very vulnerable to cystine deprivation, leading to death," Chi said. "It is almost like EMT is opens up a whole highway system (for cystine-mediated death), and therapeutically this could be very useful because there are actually compounds to block this."

Chi says the team is now in the process of testing out these cystine-blocking molecules on tumors and searching for biomarkers that will help identify when cancers are likely to respond positively to this treatment.

"Tumor cells use this EMT programming to move faster, to move around the body," Chi said. "We want to take advantage of this same pathway to cure you."

Explore further: Discovery of potential treatment for aggressive form of breast cancer

More information: X Tang et al, Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling, Oncogene (2016). DOI: 10.1038/onc.2016.394

Related Stories

Discovery of potential treatment for aggressive form of breast cancer

November 2, 2016
A new drug could be used to treat one of the most aggressive forms of breast cancer, a research centre based at University College Dublin and St Vincent's Hospital has discovered.

Promising findings towards targeted breast cancer therapy

November 14, 2016
New research led by Conway Fellow, Professor Joe Duffy and Professor John Crown in St Vincent's University Hospital has reported for the first time on a new treatment that could be used in the majority of patients with triple ...

Triple-negative breast cancer target for drug development identified

October 3, 2013
Often deadly "triple-negative" breast cancers might be effectively treated in many cases with a drug that targets a previously unknown vulnerability in the tumors, according to a UC San Francisco researcher who described ...

Nutrient deprivation kills kidney cancer cells

February 3, 2016
All cells need nutrients, but cancer cells are notoriously power hungry. As a result, cancer cells must alter their metabolism to provide the additional fuel needed for them to survive, grow and spread.

Researchers identify novel treatment for aggressive form of breast cancer

May 23, 2016
A recent study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine revealed that triple-negative breast cancer (TNBC), which has generally been unresponsive to hormone ...

A key to unlocking the mystery of triple negative breast cancer

October 24, 2016
A study conducted at the Research Institute of the McGill University Health Centre (RI-MUHC) suggests screening breast cancer patients for the prolactin receptor could improve the prognosis for patient and may help them avoid ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.